Neurocrine Biosciences Inc (NBIX) Quarterly Institutional 13F Update (Q2 2026)

NBIX ranks #681 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

NBIX is a top-conviction position for Vestal Point Capital, LP — at 7.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in NBIX belongs to BlackRock, Inc., but the position matters far more to Vestal Point Capital, LP, who has 7.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fjarde Ap-fonden /fourth Swedish National Pension Fund has added to its NBIX position for two straight quarters, increasing it by $8.0M to reach $16.5M today.

Private Client Services, LLC has trimmed its NBIX position for two straight quarters, cutting it by $1.3M while still holding $372.9K.

NBIX is down 0.9% today, but institutions show net buying of $3.7B this quarter — a divergence between today's price move and the underlying institutional flow.

NBIX posted net income of $705.5M over the trailing twelve months, and currently trades at a P/E of 19.7.

• Profitable — net income of $705.5M over the trailing twelve months
• Revenue grew 34.4% year over year
• Net income improved year over year, from $348.3M to $705.5M
• Generated $782.7M in positive operating cash flow
• Current ratio of 3.39x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.42x equity — within a conventional range